Flamingo Office

Vivida Dermatology

Atopic Dermatitis

Dermatitis

Psoriasis

Eczema

Alopecia Areata

Alopecia

CTP-543

JNJ-77242113

Dupilumab

Abrocitinib

Humira®

ABP 501

Rocatinlimab

Difamilast

Amgen

Concert Pharmaceuticals

Janssen (J&J Innovative Medicine)

Acrotech Biopharma

Pfizer

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Vivida Dermatology | Flamingo Office

Site insights

Work at this site?

Active trials

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Trial sponsors